4-Methylumbelliferyl glucuronide contributes to hyaluronan synthesis inhibition.

Abstract

4-Methylumbelliferone (4-MU) inhibits hyaluronan (HA) synthesis and is an approved drug used for managing biliary spasm. However, rapid and efficient glucuronidation is thought to limit its utility for systemically inhibiting HA synthesis. In particular, 4-MU in mice has a short half-life, causing most of the drug to be present as the metabolite 4-methylumbelliferyl glucuronide (4-MUG), which makes it remarkable that 4-MU is effective at all. We report here that 4-MUG contributes to HA synthesis inhibition. We observed that oral administration of 4-MUG to mice inhibits HA synthesis, promotes FoxP3+ regulatory T-cell expansion, and prevents autoimmune diabetes. Mice fed either 4-MUG or 4-MU had equivalent 4-MU:4-MUG ratios in serum, liver, and pancreas, indicating that 4-MU and 4-MUG reach an equilibrium in these tissues. LC-tandem MS experiments revealed that 4-MUG is hydrolyzed to 4-MU in serum, thereby greatly increasing the effective bioavailability of 4-MU. Moreover, using intravital 2-photon microscopy, we found that 4-MUG (a nonfluorescent molecule) undergoes conversion into 4-MU (a fluorescent molecule) and that 4-MU is extensively tissue bound in the liver, fat, muscle, and pancreas of treated mice. 4-MUG also suppressed HA synthesis independently of its conversion into 4-MU and without depletion of the HA precursor UDP-glucuronic acid (GlcUA). Together, these results indicate that 4-MUG both directly and indirectly inhibits HA synthesis and that the effective bioavailability of 4-MU is higher than previously thought. These findings greatly alter the experimental and therapeutic possibilities for HA synthesis inhibition.

• Authors: Nadine Nagy, Irina Gurevich, Hedwich F Kuipers, Shannon M Ruppert, Payton L Marshall, Bryan J Xie, Wenchao Sun, Andrey V Malkovskiy, Jayakumar Rajadas, Maria Grandoch, Jens W Fischer, Adam R Frymoyer, Gernot Kaber, Paul L Bollyky
• Journal: The Journal of biological chemistry (J Biol Chem) Vol. 294 Issue 19 Pg. 7864-7877 (05 10 2019) ISSN: 1083-351X [Electronic] United States
• PMID: 30914479 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: © 2019 Nagy et al.

Chemical References

• Hymecromone
• 4-methylumbelliferyl glucuronide
• Hyaluronic Acid

Topics

• Animals
• Diabetes Mellitus, Experimental (drug therapy, metabolism, pathology)
• Diabetes Mellitus, Type 1 (drug therapy, metabolism, pathology)
• Hyaluronic Acid (biosynthesis)
• Hymecromone (analogs & derivatives, pharmacology)
• Mice
• T-Lymphocytes, Regulatory (metabolism, pathology)